Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
Frederick J. Raal(University of the Witwatersrand), Stanley T. Crooke(Stanley Foundation), A. David Marais(University of Cape Town), JoAnn Flaim(Ionis Pharmaceuticals (United States)), Ju Le Tan(National Heart Centre Singapore), Raúl D. Santos(Universidade de São Paulo), Min‐Ji Charng(Taipei Veterans General Hospital), Dirk Blom(University of Cape Town), William C. Cromwell, Daniel Gaudet(Brigham and Women's Hospital), Scott Chasan-Taber, Diane L. Tribble(Lawrence Berkeley National Laboratory), Robin Lachmann(University College London)
Cited by 905
Related Papers
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
|European Heart Journal|2013|2.7k
The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes
|Nature Genetics|2000|1.8k
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2020|1.5k
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
|New England Journal of Medicine|2015|1.5k